510(k) · Cleared
ClearedOncospace
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Oncospace, Inc. · MUJ System, Planning, Radiation Therapy Treatment
Cleared on Mar 12, 2021 as substantially equivalent to K142108 (Brainlab AG, 2014) after a 212-day review. Its family tree reaches back 7 generations to 1992. 4 later devices descend from it.
- Decided
- Mar 12, 2021
- Review
- 212 days
- Class
- Class II
- Product code
- MUJ
- Recalls
- None
- Predicates
- 1
Its longest line of descent runs back 7 generations to K920879 (1992). 17 ancestors in all. 4 later devices descend from it, 1 citing it directly.
- Root · 7 generations backK920879 Brainscan Radiosurgery ModuleBrainlab · 1992 · Recalled
- 6 generations backK994413 BrainscanBrainlab AG · 2000 · Recalled
- 5 generations backK032511 Intuition ImageBrainlab AG · 2004
- 4 generations backK052220 Iplan RT FibertrackingBrainlab AG · 2005
- 3 generations backK080886 Iplan RT ImageBrainlab AG · 2008
- 2 generations backK103246 Iplan RTBrainlab AG · 2011 · Recalled
- 1 generation backK142108 RT Elements, Dose Review, Brain Metastases, Adaptive Hybrid Surgery…Brainlab AG · 2014 · Recalled
- This deviceK202284 OncospaceOncospace, Inc. · 2021
- Descendant · cites it directly · 3 of its ownK222803 OncospaceOncospace, Inc. · 2023
- Descendant · 2 generations on · 0 of its ownK253050 RadOncAIInformai · 2026
- Descendant · 2 generations on · 0 of its ownK250064 Dose+ (1.0)Mvision AI OY · 2025
- Descendant · 2 generations on · 0 of its ownK242748 OncospaceOncospace, Inc. · 2025
Most influential descendants
Showing 4 of 4 · See allView FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −7 | K920879 | Brainscan Radiosurgery Module | Brainlab | 1992 | 1 |
| −6 | K994413 | Brainscan | Brainlab AG | 2000 | 1 |
| −5 | K032511 | Intuition Image | Brainlab AG | 2004 | — |
| −4 | K052220 | Iplan RT Fibertracking | Brainlab AG | 2005 | — |
| −3 | K080886 | Iplan RT Image | Brainlab AG | 2008 | — |
| −2 | K103246 | Iplan RT | Brainlab AG | 2011 | 2 |
| −1 | K142108 | RT Elements, Dose Review, Brain Metastases, Adaptive Hybrid Surgery Analysis | Brainlab AG | 2014 | 3 |
| 0 (this device) | K202284 | Oncospace | Oncospace, Inc. | 2021 | — |
| +1 | K222803 | Oncospace | Oncospace, Inc. | 2023 | — |
| +2 | K253050 | RadOncAI | Informai | 2026 | — |
| +2 | K250064 | Dose+ (1.0) | Mvision AI OY | 2025 | — |
| +2 | K242748 | Oncospace | Oncospace, Inc. | 2025 | — |
Other ancestors by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 1997 | 1 | 0 |
| 1999 | 1 | 0 |
| 2001 | 3 | 0 |
| 2002 | 1 | 0 |
| 2004 | 1 | 0 |
| 2006 | 2 | 0 |
| 2008 | 1 | 0 |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2023 | 1 | 0 |
| 2025 | 2 | 0 |
| 2026 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in MUJ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new MUJ device
- #1 K232799 syngo.via RT Image Suitescore 18.6 · 19 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K142108 | RT Elements, Dose Review, Brain Metastases, Adaptive Hybrid Surgery AnalysisSummary page 4…sification Name: Medical charged-particle radiation therapy system (21 CFR 892.5050) Regulatory Class: II Product Code: MUJ III. PREDICATE DEVICE RT Elements, K142108 This predicate has been subject to three class 2 device recalls, one of which is still open (Z-1205-2019). IV. DEVICE… | 2014 |
What descends from it? (4)
1 later device cites it directly; ranked here by how many devices descend from each in turn.
| Number | Device | Decided | Descendants |
|---|---|---|---|
| K222803 | Oncospace | 2023 | 3 |
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 29 years and passes through 3 companies; a new generation was cleared every 3.5 years on median.
- 6 of the 17 ancestors have a recall of any class.
- Of its descendants, K222803 (Oncospace, Inc., 2023) has gone furthest, with 3 descendants of its own.
How does its category compare?
All MUJ devicesMUJ System, Planning, Radiation Therapy Treatment: FDA decisions, review times, recalls and adverse event reports over 20 years. 2021, this device’s year, is highlighted.
FDA decisions per year · MUJ
10in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · MUJ
186in 2025
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · MUJ
2in 2023
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · MUJ
21in 2025
MAUDE reports naming product code MUJ, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 4 | 67 | 4 | 24 |
| 2008 | 9 | 63 | 10 | 51 |
| 2009 | 16 | 84 | 11 | 24 |
| 2010 | 11 | 56 | 23 | 78 |
| 2011 | 9 | 103 | 17 | 73 |
| 2012 | 8 | 59 | 4 | 39 |
| 2013 | 5 | 64 | 6 | 33 |
| 2014 | 9 | 108 | 2 | 35 |
| 2015 | 13 | 78 | 7 | 30 |
| 2016 | 5 | 80 | 13 | 27 |
| 2017 | 7 | 30 | 4 | 16 |
| 2018 | 7 | 53 | 3 | 25 |
| 2019 | 9 | 56 | 4 | 25 |
| 2020 | 9 | 104 | 2 | 26 |
| 2021 | 11 | 87 | 4 | 15 |
| 2022 | 8 | 168 | 3 | 22 |
| 2023 | 10 | 140 | 2 | 76 |
| 2024 | 9 | 122 | 0 | 9 |
| 2025 | 10 | 186 | 0 | 21 |
| 2026 | 9 | 233 | 2 | — |
What is it indicated for?
Oncospace is used to configure and review radiotherapy treatment plans for a patient with malignant or benign disease in the prostate, thoracic, pancreas, or head & neck regions. It allows for set up of radiotherapy treatment protocols, association of a potential treatment plan with the protocol(s), submission of a dose prescription and achievable dosimetric goals to a treatment planning system, and review of the treatment plan. It is intended for use by qualified, trained radiation therapy professionals (such as medical physicists, oncologists, and dosimetrists). This device is for prescription use by order of a physician.
Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.
https://510kreport.com/device/K202284 · printed Nov 5, 2026
Cite this page
510(k) Report. “K202284: Oncospace.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K202284
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026